Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan + hydrochlorothiazide
Telmisartan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- History of mild-to-moderate hypertension
- Patients who fail to respond adequately to telmisartan monotherapy
- Participants between 18 and 80 years of age
- Willingness and ability to provide written informed consent
Exclusion Criteria:
- Patients taking more than three anti-hypertensive medications at the screening visit
Pre-menopausal women
- Who are not surgically sterile
- Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
Any women:
- Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 3)
- Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters
- SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
- Serum creatinine > 2.3 mg/dL
- Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
- Known or suspected secondary hypertension
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
- Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
- Unstable angina within the past three months
- Stroke within the past six months
- Myocardial infarction or cardiac surgery within the past three months
- PTCA (percutaneous transluminal coronary angioplasty) within the past three months
- History of symptoms characteristic of angioedema during treatment with ACE inhibitors, angiotension II antagonists, thiazide diuretics, β-blockers or calcium channel blockers
- Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- Administration of digoxin or other digitalis-type drugs
- Patients with Type I or Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
- Known drug or alcohol dependency within the past one year period
- Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
- Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan (except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.321 open-label extension study) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
- Known hypersensitivity to any component of the formulations
- Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Telmisartan + hydrochlorothiazide and matching placebo
Telmisartan and matching placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in seated diastolic blood pressure (DBP)
Secondary Outcome Measures
Change from baseline in seated systolic blood pressure (SBP)
Blood pressure control
Systolic blood pressure response
Incidence of adverse events
Change from baseline in physical examination
Change from baseline in heart rate
Change from baseline in laboratory parameters
Change from baseline in 12-lead ECG (electrocardiogram)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177500
Brief Title
Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy
Official Title
An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
January 2000 (undefined)
Primary Completion Date
May 2000 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and systolic blood pressure in patients who fail to respond adequately to telmisartan monotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
327 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan + hydrochlorothiazide and matching placebo
Arm Type
Experimental
Arm Title
Telmisartan and matching placebo
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Telmisartan + hydrochlorothiazide
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in seated diastolic blood pressure (DBP)
Time Frame
baseline and after 8 weeks of treatment
Secondary Outcome Measure Information:
Title
Change from baseline in seated systolic blood pressure (SBP)
Time Frame
baseline and after 8 weeks of treatment
Title
Blood pressure control
Time Frame
8 weeks
Title
Systolic blood pressure response
Time Frame
8 weeks
Title
Incidence of adverse events
Time Frame
up to 16 weeks
Title
Change from baseline in physical examination
Time Frame
Baseline and day 56
Title
Change from baseline in heart rate
Time Frame
Baseline, day 28 and 56
Title
Change from baseline in laboratory parameters
Time Frame
Baseline and day 56
Title
Change from baseline in 12-lead ECG (electrocardiogram)
Time Frame
Baseline and day 56
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of mild-to-moderate hypertension
Patients who fail to respond adequately to telmisartan monotherapy
Participants between 18 and 80 years of age
Willingness and ability to provide written informed consent
Exclusion Criteria:
Patients taking more than three anti-hypertensive medications at the screening visit
Pre-menopausal women
Who are not surgically sterile
Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
Any women:
Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 3)
Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters
SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
Serum creatinine > 2.3 mg/dL
Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
Known or suspected secondary hypertension
Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
Unstable angina within the past three months
Stroke within the past six months
Myocardial infarction or cardiac surgery within the past three months
PTCA (percutaneous transluminal coronary angioplasty) within the past three months
History of symptoms characteristic of angioedema during treatment with ACE inhibitors, angiotension II antagonists, thiazide diuretics, β-blockers or calcium channel blockers
Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
Administration of digoxin or other digitalis-type drugs
Patients with Type I or Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
Known drug or alcohol dependency within the past one year period
Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan (except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.321 open-label extension study) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
Known hypersensitivity to any component of the formulations
Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.323_U00-3262.pdf
Description
Related Info
Learn more about this trial
Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy
We'll reach out to this number within 24 hrs